Medicine Platform
搜索
Product Catagories
首页 > Pharmaceutical Materials > USP Lopinavir 192725-17-0
USP Lopinavir 192725-17-0
单价 面议对比
询价 暂无
发货 全国
过期 长期有效
更新 2025-08-13 23:40
 
详细信息

Grade: Pharmaceutical Grade

Factory Location: Xiamen, Fujian

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East

Monthly Production Capacity: 1000kg

Packaging Information: 25kg/drum 1kg/bottle

Delivery Lead Time: 7 days after payment

Sample Provided: yes

Payment Terms: L/L

 

Product Information

 

Product name

Lopinavir

CAS No.

192725-17-0

Molecular Formula

C37H48N4O5

Molecular Weight

628.801

Quality Standard

99% up, USP42, Medicine Grade

Appearance

White powder

 

COA of Lopinavir

 

TEST

SPECIFICATION

RESULTS

Description

White  powder

Complies

Identification

IR

Complies

 

HPLC

Complies 

Heavy metal

≤10ppm

5ppm

Pb

≤3ppm

1.5ppm

Hg

≤0.1ppm

0.05ppm

Cd

≤1ppm

0.2ppm

Loss on drying

≤0.5%

0.12

Residue on lgnition

≤0.1%

0.03

Single impurity

≤0.5%

0.12

Total impurity

≤1.0%

0.29

Total bacteria

≤1000cfu/g

<1000

Yeast and Mould

≤100 cfu/g

<000

E.coli/25g

Absent

Absent

Salmonella/25g

Absent

Absent

Assay

≥99.0%

99.4%

Conclusion

Conforms with USP/EP standards

 

Usage

 

Function of Lipinavir

Lipinavir is used in combination with other antiretroviral drugs to treat human immunodeficiency virus-1 (HIV-1) infection in adults and children over 2 years old.

Lopinavir is an HIV protease inhibitor, which can block the division of Gag-Pol polyprotein, resulting in the production of immature, non-infectious virus particles; ritonavir is a kind of HIV-1 and HIV- 2 Peptidomimetic inhibitors of aspartyl protease activity. By inhibiting HIV protease, the enzyme cannot process the precursor of Gag-Pol polyprotein, resulting in the formation of immature HIV particles, which prevents the start of a new infection cycle. Ritonavir can inhibit CYP3A-mediated metabolism of lopinavir, resulting in a higher concentration of lopinavir.

Antiviral activity of Lopinavir: In vitro antiviral drug activity studies in combination with lopinavir have shown that the combination of lopinavir and nelfinavir will increase the antagonistic effect, and it can be compared with amprenavir, atazanavir and indinavir The combined application of Vivi, Saquinavir and Telanavir will increase the synergy. The EC50 value of lopinavir for three different HIV-2 virus strains is between 12~180nM (0.008~113 μg/mL).